Intralesional PPD for Verruca Vulgaris: Protocol and Expected Outcomes
Intralesional purified protein derivative (PPD) immunotherapy is an effective treatment for verruca vulgaris, with complete clearance rates of 75-81% after 3-5 treatment sessions given every 2 weeks, and works by stimulating cell-mediated immunity against HPV.
Treatment Protocol
Dosing and Administration
- Dose: 0.1 mL of PPD (5-10 Tuberculin Units) injected intralesionally into the largest or oldest wart 1, 2, 3
- Frequency: Every 2 weeks until complete clearance or maximum of 4-6 sessions 2, 3, 4
- Injection technique: Direct intralesional injection into the index wart after local anesthesia if needed
Single vs Multiple Wart Injection Strategy
For patients with multiple warts, injecting multiple warts (not just one) provides superior clearance rates (79.3% vs 58.6%) and faster response, though with more pain 5. The distant wart effect occurs regardless, but treating multiple lesions accelerates clearance.
Pre-treatment Considerations
- Paring or debridement of thick keratin is recommended before injection to enhance penetration 6
- Mantoux testing is not required before treatment 4
- PPD can be used even in immunocompromised patients with good safety 7
Expected Outcomes
Efficacy Rates
- Complete clearance: 75-81% of patients achieve complete resolution 1, 2, 3
- Response in injected warts: 83-93% clearance rate 1
- Distant wart clearance: 45-81% of untreated warts clear due to systemic immune response 3, 5
- Average sessions to clearance: 3-4 treatments (range 1-5 sessions) 3, 5
Timeline
- Most responses occur after 3-5 sessions over 6-12 weeks 1, 3
- Complete responders should be followed for 3-6 months to monitor for recurrence 3, 4
Recurrence Rates
Recurrence is rare (0-12.5%) after successful clearance, with most studies showing no recurrence during 6-month follow-up 1, 3, 5, 4. This compares favorably to destructive methods.
Adverse Effects and Safety
Common Side Effects
- Pain at injection site: Most common, more pronounced with multiple injections 5
- Local erythema and edema: Expected inflammatory response 4
- Mild inflammation: Generally well-tolerated 1
Serious Complications
PPD has a superior safety profile compared to other intralesional agents like zinc sulfate, with significantly lower rates of necrosis and scarring 1. No systemic adverse effects have been reported in the literature 4, 7, 8.
Clinical Context from Guidelines
While the 2014 British Association of Dermatologists guidelines 6 mention intralesional immunotherapy with Candida, mumps, and tuberculin antigens showing clearance rates of 47-87%, they note there is "no robust evidence" and classify it as Level 1 evidence with mixed quality. However, the more recent research (2019-2025) consistently demonstrates PPD's efficacy and safety, particularly for recalcitrant warts that have failed cryotherapy 3.
Practical Considerations
Best Candidates
- Multiple warts at different anatomic sites
- Cryotherapy-resistant or recalcitrant warts 3
- Pediatric patients (better tolerated than destructive methods) 1
- Immunocompromised patients (safe and effective) 7
- Periungual and palmoplantar warts 9
When to Stop Treatment
- Complete clearance achieved
- After 6 sessions with no response (non-responders: 5-24%) 2, 4
- Intolerable side effects (rare)
Storage and Handling
PPD must be stored at 2-8°C, protected from light, and discarded 30 days after vial entry 10. Do not freeze.
The mechanism works through non-specific stimulation of cell-mediated immunity, triggering a systemic immune response against HPV that clears both treated and distant warts 4, 8. This is particularly valuable in countries with high tuberculosis prevalence where PPD sensitivity is common 8.